Dr. Mark Geier, M.D., Ph.D and David Geier
Dr. Mark Geier has an M.D., Ph.D in genetics. He is board certified in genetics by the American Board of Medical Genetics and is a Fellow of the American College of Epidemiology. Dr. Geier is founder of ASD Centers, LLC, and has been in clinical practice for more than 29 years. Dr. Geier is president of the 501(c)3 non-profit Institute of Chronic Illnesses, Inc. and is a founder of the the 501(C)3 nonprofit CoMeD, Inc.
Dr. Geier was a researcher at the National Institutes of Health for ten years. He was also a professor at the Johns Hopkins University and at the Uniformed Services University of the Health Sciences. Dr. Geier has addressed the Institute of Medicine of the US National Academy of Sciences, the US State Department, the Government Reform Committee of the US House of Representatives, and numerous other professional meetings. Dr. Geier has authored over 100 peer-reviewed medical studies, and recently, has co-authored more than fifty peer-reviewed medical studies on vaccine safety, efficacy and policy. In addition, Dr. Geier has authored more than twenty peer-reviewed medical studies on patients diagnosed with autistic disorders. His research has won awards and has received national and international media coverage.
Dr. Geier has participated in the evaluation and treatment of more than 600 patients diagnosed with autism spectrum disorders. He has served as a scientific reviewer for autism grants for the U.S. Government. Dr. Geier has a patent pending for the treatment of patients diagnosed with autism spectrum disorders.
Dr. Geier has also been involved in vaccine/biologic litigation.
Dr. Geier has also been involved in vaccine/biologic litigation.
David Geier is president of MedCon, Inc. and is vice-president of the non-profit 501(c)3 Institute of Chronic Illnesses, Inc. David is a founder of the non-profit 501(c)3 CoMeD, Inc. He graduated with honors from the University of Maryland with a B.A. in biology and a minor in history. He has been a researcher scientist at the National Institutes of Health.
David has co-authored approximately fifty peer-reviewed medical studies on vaccine safety, efficacy, and policy. He has received critical acclaim from his
colleagues for his research on vaccines by winning the “Stanley W. Jackson Prize,” which is given to authors having the best paper in the preceding three years in the Journal of the History of Medicine and Allied Sciences published by Duke University. He has addressed numerous professional meetings, and has recently twice co-addressed the Institute of Medicine of the United States’ National Academy of Sciences on vaccine issues.
colleagues for his research on vaccines by winning the “Stanley W. Jackson Prize,” which is given to authors having the best paper in the preceding three years in the Journal of the History of Medicine and Allied Sciences published by Duke University. He has addressed numerous professional meetings, and has recently twice co-addressed the Institute of Medicine of the United States’ National Academy of Sciences on vaccine issues.
Over the last few years David, as a member of the Institute of Chronic Illnesses, has been studying and publishing on the relationship of genetic, biochemical and hormonal changes in autism which has resulted in new insights as to the cause and treatment of autism and other chronic illnesses. Overall, David has authored more than twenty peer-reviewed medical studies on patients diagnosed with autistic disorders. David has a patent pending for the treatment of patients diagnosed with autism spectrum disorders. David has also been involved in vaccine/biologic litigation.
Dr. Mark R. Geier, M.D., Ph.D.
David Geier
